Evidence map›Paper›PMID 32326589›Full record

ReviewInternational journal of molecular sciences2020

The Interplay between Diabetes and Alzheimer's Disease-In the Hunt for Biomarkers.

Adriana Kubis-Kubiak, Aleksandra Dyba, Agnieszka Piwowar

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Adriana Kubis-KubiakDepartment of Toxicology, Faculty of Pharmacy, Wroclaw Medical University, 50367 Wroclaw, Poland.ORCID 0000-0001-6823-1268
Aleksandra DybaStudents Science Club of the Department of Toxicology, Faculty of Pharmacy, Wroclaw Medical University, 50367 Wroclaw, Poland.
Agnieszka PiwowarDepartment of Toxicology, Faculty of Pharmacy, Wroclaw Medical University, 50367 Wroclaw, Poland.ORCID 0000-0001-6971-3883
Wroclaw Medical University · PL

Funding

Ministry of Science and Higher Education in the "Regional Initiative of Excellence" programme for the years 2019-2022 016/RID/2018/19
6 · The paper itself

Abstract

The brain is an organ in which energy metabolism occurs most intensively and glucose is an essential and dominant energy substrate. There have been many studies in recent years suggesting a close relationship between type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD) as they have many pathophysiological features in common. The condition of hyperglycemia exposes brain cells to the detrimental effects of glucose, increasing protein glycation and is the cause of different non-psychiatric complications. Numerous observational studies show that not only hyperglycemia but also blood glucose levels near lower fasting limits (72 to 99 mg/dL) increase the incidence of AD, regardless of whether T2DM will develop in the future. As the comorbidity of these diseases and earlier development of AD in T2DM sufferers exist, new AD biomarkers are being sought for etiopathogenetic changes associated with early neurodegenerative processes as a result of carbohydrate disorders. The S100B protein seem to be interesting in this respect as it may be a potential candidate, especially important in early diagnostics of these diseases, given that it plays a role in both carbohydrate metabolism disorders and neurodegenerative processes. It is therefore necessary to clarify the relationship between the concentration of the S100B protein and glucose and insulin levels. This paper draws attention to a valuable research objective that may in the future contribute to a better diagnosis of early neurodegenerative changes, in particular in subjects with T2DM and may be a good basis for planning experiments related to this issue as well as a more detailed explanation of the relationship between the neuropathological disturbances and changes of glucose and insulin concentrations in the brain.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBiomarkersBrainCarbohydratesDiabetes Mellitus, Type 2HumansHyperglycemiaS100 Calcium Binding Protein beta Subunittau ProteinsAmyloid beta-PeptidesBiomarkersCarbohydratesS100B protein, humanS100 Calcium Binding Protein beta Subunittau ProteinsAlzheimer’s diseasebiomarkersdiabetes mellitusS100 proteins

Identifiers

PMID32326589
PMCPMC7215807
OpenAlexW3016333202

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.